Observational studyThoracic cancer2022

Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.

Tomoki Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.